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Although mutations in the oncoprotein murine double minute 2 (MDM2) are rare, MDM2 gene overexpression has
been observed in several human tumors. Given that even modest changes in MDM2 levels might influence the p53
tumor suppressor signaling pathway, we postulated that sequence variation in the promoter region of MDM2 could
lead to disregulated expression and variation in gene dosage. Two promoters have been reported for MDM2; an
internal promoter (P2), which is located near the end of intron 1 and is p53-responsive, and an upstream
constitutive promoter (P1), which is p53-independent. Both promoter regions contain DNA variants that could
influence the expression levels of MDM2, including the well-studied single nucleotide polymorphism (SNP) SNP309,
which is located in the promoter P2; i.e., upstream of exon 2. In this report, we screened the promoter P1 for DNA
variants and assessed the functional impact of the corresponding SNPs. Using the dbSNP database and genotyping
validation in individuals of European descent, we identified three common SNPs (−1494 G>A; indel 40 bp; and
−182 C >G). Three major promoter haplotypes were inferred by using these three promoter SNPs together with
rs2279744 (SNP309). Following subcloning into a gene reporter system, we found that two of the haplotypes
significantly influenced MDM2 promoter activity in a haplotype-specific manner. Site-directed mutagenesis
experiments indicated that the 40 bp insertion/deletion variation is causing the observed allelic promoter activity.
This study suggests that part of the variability in the MDM2 expression levels could be explained by allelic p53-
independent P1 promoter activity.
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The p53 tumor suppressor has a key role in orchestrat-
ing cellular responses to various types of stresses, includ-
ing DNA damage and oncogene activation with
apoptosis, cell-cycle arrest, senescence, DNA repair, cell
metabolism, or autophagy [1,2]. Malfunction and muta-
tions of p53 have been found in most human cancers,
leading to a deregulated p53 activity that allows cells to
proliferate and survive [3]. The activity of p53 is regu-
lated by many proteins, and one of the most extensively
studied regulators of p53 is the murine double minute 2
(MDM2) oncoprotein. MDM2 can regulate p53 activity
in different ways and even modest modifications of
MDM2 levels can affect the p53 pathway [4]. Firstly,
MDM2 directly binds to the p53 transactivation domain,* Correspondence: daniel.sinnett@umontreal.ca
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reproduction in any medium, provided the orthus inhibiting its transcriptional activity. Secondly,
MDM2 promotes ubiquitin-dependent proteasomal deg-
radation of p53 by functioning as an E3 ubiquitin ligase
[5,6]. Finally, MDM2 shuttles p53 out of the nucleus to
the cytoplasm of the cell, promoting the degradation of
p53. Importantly, MDM2 forms a negative-feedback
loop in regulating p53 activity, in which p53 induces
transcription of MDM2, and, in turn, the MDM2 protein
inhibits p53 activity (reviewed by Momand et al. [7]).
Although mutations in MDM2 are rare, MDM2 over-
expression is observed in a number of human tumors
due to various mechanisms including gene amplification
[8-10] and increased transcription [11,12]. MDM2 over-
expression predisposed transgenic mice to spontaneous
tumor formation [13] and therefore, overexpression of
MDM2 may substitute for inactivating mutations in p53
[9]. Because MDM2 is an important negative regulator
of p53 activity, overexpression of MDM2 can result inl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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thereby promoting human carcinogenesis.
Functional sequence variants in promoter regions can
lead to variable gene expression levels [14,15]; single nu-
cleotide polymorphisms (SNPs) in promoters of genes
implicated in DNA-damage responses and apoptosis
could have an impact in an individual's susceptibility to
develop cancer [16-21]. Because MDM2 is a key compo-
nent of the p53-mediated DNA-damage response, pro-
moter SNPs in this gene might influence this highly
regulated pathway by modifying cellular MDM2 protein
levels [22]. The MDM2 gene has a basal promoter (P1)
and an alternative promoter (P2) starting in the intron 1
[23]. The promoter P2 contains a p53-responsive elem-
ent and has been shown to regulate MDM2 levels in
stressed cells, whereas the promoter P1 functions mainly
in a non-stressed environment [23,24]. The rs2279744
(SNP309) in the intronic p53-responsive promoter of the
MDM2 gene has been shown to increase the affinity of
the transcriptional activator Sp1, resulting in higher
levels of MDM2 mRNA and protein. This SNP has been
shown to attenuate apoptotic activity and accelerate
tumor formation [22,25-27]. Several studies have
reported associations between rs2279744 and the risk of
different types of cancer [28-30]; however, this associ-
ation has not always been confirmed [31-33]. In an at-
tempt to obtain a more complete view of the MDM2
promoters, we determined the SNP content and the
haplotype structure of the constitutive P1 promoter.
Here, we show that distinct P1 promoter haplotypes can
influence the p53-independent promoter activity in an
allele-specific manner.
Methods
SNP discovery in MDM2 proximal promoter region
The initial search for promoter SNPs (pSNPs) in MDM2
proximal promoter defined as 2.0 kb upstream of the tran-
scription start site was done using the dbSNP database
(build 128) [34]. Seven SNPs were selected for genotyping
in a panel of 91 individuals of Western European descent.
The Institutional Review Board approved the research
protocol and informed consent was obtained from all par-
ticipants. The corresponding promoter region was ampli-
fied in one polymerase chain reaction (PCR) fragment in a
50μL reaction volume, using the following conditions: 20
pmole of 50AAAGCCCAAATTTCCTTGCT30 (forward)
and 50CTCCATCTTTCCGACACACA30 (reverse) pri-
mers, 2 mM MgCl2, 0.2 mM deoxynucleoside tripho-
sphates (dNTPs), 1× Fast Start Taq DNA polymerase
buffer and GC rich buffer, 2U Fast Start Taq DNA poly-
merase (Roche Diagnostics, Laval, Canada) and 15 ng of
genomic DNA. The PCR program was 95°C for 3 min; 10
cycles with a denaturation at 95°C for 15 s; annealing at
55–50°C (each cycle decreases by 0.5°C) for 20 s andelongation at 68°C for 2 min; followed by 25 cycles at 50°
C for annealing. The amplicons were dot-blotted in dupli-
cate on a nylon membrane and were hybridized with
allele-specific oligonucleotides (ASOs) as previously
described [35]. Oligonucleotide probes specific for each
promoter SNP were used for ASO analysis and are avail-
able upon request. A 40 bp insertion/deletion (indel) poly-
morphism was genotyped by amplification of a 260 bp
fragment containing the indel region followed by electro-
phoresis of the resulting amplicons on a 3% agarose gel
to detect one (homozygous) or two bands (heterozy-
gous). PCR conditions were as follows: 20 pmole of
50TTTCCTTTCTGGTAGGCTGG30 (forward) and
50CACCTACTTTCCCACAGAGA30 (reverse) primers,
1.5 mM MgCl2, 0.2 mM dNTPs, 1× Fast Start Taq
DNA polymerase buffer and GC rich buffer, 1U Fast
Start Taq DNA polymerase (Roche Diagnostics, Laval,
Canada), and 15 ng of genomic DNA. The PCR pro-
gram was 95°C for 3 min; 32 cycles with a denaturation
at 95°C for 30 s; annealing at 52°C for 30 s; and elong-
ation at 72°C for 20 s. Hardy-Weinberg equilibrium was
tested with a χ2 test for goodness of fit. Haplotypes
were generated by PHASE software (version 2; Univer-
sity of Washington, Seattle, WA, USA) [36].
Gene reporter assays and site-directed mutagenesis
Constructs
The two major promoter haplotypes (approximately
2.0 kb region) were amplified from genomic DNA of
known homozygous individuals and cloned individually
in the promoterless pGL3basic Firefly luciferase vector
(Promega Corp., Fitchburg, WI, USA) using the Gateway
Technology (Invitrogen Corporation, Carlsbad, CA,
USA). Specific mutations were introduced by site-
directed mutagenesis (Quickchange multi site-directed
mutagenesis kit, Stratagene from Agilent Technologies,
Santa Clara, CA, USA) according to the manufacturer's
instructions. Clones chosen for transfection were
sequenced to confirm the presence of the SNPs and then
purified using the Qiagen plasmid mini kit (Qiagen
Company, Toronto, Canada) prior to transfection.
Transfection
The resulting constructs were used to transiently trans-
fect three cell lines (HeLa, HepG2, and JEG3) using lipo-
fectamine reagent according to the manufacturer's
protocol (Invitrogen). Constructs (99 ng) and SV40-
driven (1 ng) Renilla luciferase cytomegalovirus (CMV)
immediate early enhancer/promoter region (pRL-CMV)
(ratio 100:1) were co-transfected to control transfection
efficiency. The pGL3basic promoterless plasmid (Pro-
mega) was used as a negative control and the pGL3SV40
plasmid (Promega) was used as a positive control. The
transfected cells were plated in 96-well plates with
Figure 1 Schematic illustration of MDM2 basal (P1) and internal
(P2) promoters. The promoter positions were numbered with
respect to the first nucleotide of the first exon as +1, and the
nucleotide immediately upstream as −1. The positions of the
investigated promoter SNPs are indicated.
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vested 24 h following transfection, and luciferase re-
porter gene activity was measured with dual-luciferase
reporter assay system (Promega) in a SpectraMax 190
luminometer according to the manufacturer's protocol
(Molecular Devices, LLC, Sunnyvale, CA, USA). Firefly
luciferase activities of the allelic constructs were normal-
ized using the Renilla luciferase pRL-CMV activity. The
results were expressed as the ratio of Firefly luciferase
activity divided by the pRL-CMV internal control activ-
ity and expressed as relative luciferase (means ± standard
deviation) of four replicates. Three independent experi-
ments were carried out for each cell line. Statistical ana-
lyses were performed using unpaired Student's t test to
determine p values. Global p value is calculated with
Fischer's inverse Chi-squared test [37].In silico predictions of putative TFBS
MatInspector program from Genomatix Software GmbH
(Bayerstrasse, Munich, Germany, www.genomatix.de)
was used to determine the presence of putative binding
sites for known transcription factors. The predicted gain
or loss of putative transcription factor binding site
(TFBS) due to a given SNP was determined by the opti-
mized matrix threshold as defined in the MatInspector
program.Results
The search for SNPs in the constitutive P1 promoter of
MDM2 led to the identification of eight pSNPs, including
a 40 bp indel (see Table 1). In addition to these pSNPs, we
included the well-studied rs2279744 located in the P2 pro-
moter for haplotype analysis (see Figure 1 for a schematic
representation of MDM2 promoters). By genotyping a
panel of 91 unrelated Western Europeans, we found four




rs2904506 g.67,487,080 T >G
rs3930427 g.67,487,082 C >G
rs3730486 g.67,487,509 C > T
rs3730487 g.67,487,563A>G
rs937282 g.67,488,064 C >G
rs3730491 g.67,488,095 C > T
rs2279744e g.67,488,847 T >G
aFrom dbSNP build 128.
bNCBI Build 36.1.
cPosition relative to the transcription start site (based on reference sequence mRNA
dMinor allele frequencies (MAF) were calculated with 91 unrelated European individ
eFor comparison purposes, we included SNP309 (+601 in our nomenclature) associa−182 C>G, rs937282; and SNP309/601 T>G, rs2279744)
to be polymorphic. For rs2279744 the observed minor al-
lele frequency of 35% was similar to the one previously
reported for Caucasians [38]. Among the five non-
polymorphic SNPs, both −1166 T>G (rs2904506) and
−1164 C>G (rs3930427) are located in the 40 bp indel se-
quence thus creating in some individuals a near identical
(except for 2 bps) tandem duplication. Therefore, indivi-
duals carrying the deletion behave like they have different
alleles at these two positions. Because single variants
might not be sufficient to capture the genetic variability
relative to a given phenotype, we constructed haplotypes
using all four polymorphic pSNPs. Based on these data,
we estimated haplotype phase and the corresponding fre-
quencies (Table 2). The three most common promoter
haplotypes (1A, 1B, and 2) represented 92.3% of the
observed haplotypes in Europeans. Haplotypes 1A and 1B
differ at rs2279744, whereas haplotype 2 differs at all four
positions (Figure 2a). To evaluate the extent of linkage dis-
equilibrium between the SNPs studied, we measured D0promoter
SNPs IDc MAFd
−1494 25%









uals in this study.
ted with the internal promoter P2.
Table 2 Most frequent MDM2 promoter haplotypes
Haplotype −1494 G>A 40 bp deletion −182 C>G +309 T>G Frequencya
1A A No deletion C G 36.8%
1B A No deletion C T 17.0%
2 G Deletion G T 38.5%
aFrequencies calculated with genotyping results of the 91 unrelated European individuals.
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0.977 and 0.934, respectively, and 0.968 and 0.471 between
these two SNPs and rs2279744. This indicates that
rs2279744 (SNP309) is tightly linked with the P1 promo-
ter's variants.
To assess the functional impact of the major promoter
haplotypes 1 and 2, we subcloned the promoter haplo-
types in the promoterless pGL3 basic Firefly luciferase
reporter vector and we carried out transient transfection
experiments for each haplotype-specific constructs in
three cell lines (Figure 2b). Because these constructs
contain only the proximal P1 promoter (rs2279744 was
not included), we could not test differential promoter
activities between haplotypes 1A and 1B. SignificantFigure 2 Gene reporter assays to evaluate the functional impact of th
representation of constructs tested for luciferase gene reporter assays in pG
excluding the position +309 T >G (see Table 2). (B) Relative luciferase activ
transfection in HeLa, HepG2 and JEG3 cells. The empty promoterless pGL3
ratio of Firefly/Renilla activity multiplied by 100. Promoter haplotype H2 wa
Haplotype H1 showed significantly higher expression levels across all three
unpaired student's t test. Significant differences are marked with an asteriskdifferences were found between H1 and H2 (Figure 2a),
with the promoter haplotype H1 having stronger pro-
moter activity in all cell lines tested (Figure 2b). The rela-
tive luciferase activity driven by H1 was up to 2.3-fold
higher than the luciferase levels driven by H2, indicating
variable haplotype-specific expression levels of MDM2.
The 309 G allele was only present in 1.0% of individuals
carrying haplotypes other than H1A (data not shown);
therefore, European individuals carrying the allele G of
this SNP are more likely to have the high P1 promoter ac-
tivity haplotype because of the linkage disequilibrium.
Using in silico predictive tools, none of these SNPs
seem to affect the putative binding of known transcrip-
tion factors. However, the 40 bp indel contains severale most frequent MDM2 basal promoter haplotypes. (A) Schematic
L3 basic vector. Haplotypes H1A and H1B are identical when
ity of MDM2 promoter haplotypes was measured following transient
basic vector was used as negative control. Results are expressed in a
s used as reference against which relative expression was compared.
cell lines. The p values are calculated from four replicates with
(*p<3× 10−3; **p<8× 10−6).
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shown). In an attempt to identify the cis-acting elements
responsible for the observed changes in MDM2 P1
promoter activity, we modified the allele combination
in both haplotypes using site-directed mutagenesis
(Figure 3). None of the allele combinations in the
context of the 40 bp insertion (defining H1) signifi-
cantly affected the promoter activity of the corre-
sponding H1-derived haplotypes. In the context of
the 40 bp deletion (defining H2), the −1494A >G
variant (rs1144944) does not affect the H2-derived
promoter activity. However, the introduction of allele
−182 C (instead of allele G) completely abrogated the
promoter activity when combined with the 40 bp de-
letion compared to the H1-derived construct. This
indicates the role of the 40 bp indel variation in the
observed allelic promoter activity and the presence of
a putative cis-acting element at position −182. Taken
together, these results support the functional impact
of MDM2 promoter haplotypes on the promoter
activity.
Discussion
In more than half the tumors with a fault in the p53
pathway, TP53 itself is not mutated but the p53 pathwayFigure 3 Functional analyses of MDM2 promoter haplotype H1- and H
carrying mutations introduced by site-directed mutagenesis and tested for
Relative luciferase activity of the H1- and H2-derived promoter haplotypes
panel). The empty promoterless pGL3 basic vector was used as negative co
multiplied by 100. Promoter haplotype H2 was used as reference against w
from four replicates with unpaired student’s t test. The p value between H1is abrogated. Mechanisms that result in this abrogation
include increased expression of MDM2 [7] and deletion
or epigenetic inactivation of the p53-positive regulator
and MDM2 inhibitor ADP-ribosylating factor [39,40].
MDM2 might influence cancer risk through its inter-
action with other key cancer genes with various func-
tions [41-44]. The MDM2 oncogene is overexpressed in
various human cancers and its expression correlates with
the phenotypes of high-grade, late-stage, and resistant
tumors [45,46]. MDM2 has an important role in cancer
development, mostly through inactivation of the p53
pathway [46]. By contrast, the p53-independent MDM2-
mediated tumorigenesis is less understood.
At the promoter level, regulation of MDM2 expression
is complex involving two promoters, P1 and P2, which
govern transcripts with different translational potentials.
In this report, we characterized the two major haplotypes
that correspond to the upstream p53-independent consti-
tutive P1 promoter. Unlike the p53-responsive P2 pro-
moter, the P1 promoter lacks an identified TATA box and
p53-responsive element [23,47]. We showed that the con-
stitutive expression levels of MDM2 might at least be par-
tially regulated by distinct promoter SNPs, particularly the
40 bp deletion and the corresponding promoter haplo-
types (see Results section). Previous work has shown a2-derived mutations in HeLa cells. H1- and H2-derived constructs
luciferase gene reporter assays in pGL3 basic vector (left panel).
was measured following transient transfection in HeLa cells (right
ntrol. Results are expressed in a ratio of Firefly/Renilla activity
hich relative expression was compared. The p values are calculated
and H2 is 0.0008.
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activity, with the allele −182 G having high promoter activ-
ity [48]. However, in our hands, the −182 G allele was
associated with the low-activity P1 promoter haplotype.
This discrepancy could be explained by the fact that the
extended promoter P1 haplotype was not determined in
their study. The latter is particularly relevant when consid-
ering the observed impact of the SNP-182 C>G alleles in
the context of the presence/absence of the 40 bp deletion.
Most previous studies have been focused on the im-
pact of rs2279744 (SNP309 (T >G)), which is located in
the p53-dependent promoter P2. In vitro studies have
shown that the allele SNP309G increased the affinity of
Sp1 transcription activator for a putative binding site
and increase the steady-state levels of MDM2, which in
turn reduced the basal p53 levels [26,49]. Although
many studies have attempted to assess the association
between rs2279744 and different cancer types, the data
remains controversial [27,38,50]. A clear association be-
tween rs2279744 and cancer risk was reported in Asians
but not in Europeans and in Africans in a meta-analysis
[38]. The explanation for this observation is unclear but
could be explained by genetic heterogeneity because the
observed SNP309 frequencies are variable in different
populations ranging from approximately 50% in Asians to
33% and 10% in Caucasians and Africans, respectively [38].
A recent meta-analysis indicates that MDM2 SNP309
serves as a tumor susceptibility marker [51]. Finally, the
transcription factor influenced by rs2279744 might be
cell-type specific so that this variant does not affect
MDM2 expression in certain tissues [22].
These conflicting rather than conclusive results might
be explained by several reasons, including linkage dis-
equilibrium between SNP309 and another, yet unknown,
functional SNP in MDM2. This linkage disequilibrium
could also contribute to cancer associations with SNP309
suggesting that haplotype constructions of MDM2 pSNPs
would add force to these association studies. In this
report, we showed that SNP309G was associated with
the high P1 promoter activity haplotype. We believe
that looking at the impact of haplotypes rather than
individual SNPs on promoter activity is a more suit-
able approach because it takes into account the puta-
tive interaction between SNPs. In conclusion, this study
revealed differential constitutive P1 promoter activities, at
least in vitro. This observation implies that individuals
who carry distinct p53-independent P1 promoter hap-
lotypes might have a modified risk for cancer devel-
opment. Association studies in large patient cohorts
will helps us to further determine the importance of
these haplotypes in cancer.Competing interests
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